Výsledky vyhledávání - "Benoît Pochon"

Supplementary Table 1 from The Novel ATP-Competitive Inhibitor of the MET Hepatocyte Growth Factor Receptor EMD1214063 Displays Inhibitory Activity against Selected MET-Mutated Variants

Autor: Yitzhak Zimmer, Friedhelm Bladt, Andree Blaukat, Daniel M. Aebersold, Adrian Keogh, Deborah Stroka, Paola Francica, Wieslawa Blank-Liss, Bruno Streit, Benoît Pochon, Michaela Medová

PDF - 35KB, Supplementary table 1 - Fold increase in dead cells upon EMD1214063 treatment as compared to untreated cells in eight studied MET mutated variants.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14118908b3736aeb5e795279c596eb59
https://doi.org/10.1158/1535-7163.22499346.v1

Zobrazit plný text záznamu

Supplementary Figure 1 from The Novel ATP-Competitive Inhibitor of the MET Hepatocyte Growth Factor Receptor EMD1214063 Displays Inhibitory Activity against Selected MET-Mutated Variants

Autor: Yitzhak Zimmer, Friedhelm Bladt, Andree Blaukat, Daniel M. Aebersold, Adrian Keogh, Deborah Stroka, Paola Francica, Wieslawa Blank-Liss, Bruno Streit, Benoît Pochon, Michaela Medová

PDF - 2667KB, Supplementary figure 1 - Impact of EMD1214063 treatment on the viability of NIH3T3 MET M1268T and Y1248H variants.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::441c68e9acb6e3a0a086ec8848673494
https://doi.org/10.1158/1535-7163.22499355.v1

Zobrazit plný text záznamu

Targeting of the MET receptor tyrosine kinase by small molecule inhibitors leads to MET accumulation by impairing the receptor downregulation

Autor: Benoît Pochon, Michaela Medová, Paola Francica, Wieslawa Blank-Liss, Dominic Leiser, Daniel M. Aebersold, Yitzhak Zimmer, Astrid A. Glück

Publikováno v: FEBS Letters

The MET receptor tyrosine kinase is deregulated primarily via overexpression or point mutations in various human cancers and different strategies for MET inhibition are currently evaluated in clinical trials. We observed by Western blot analysis and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66ca48ca4f6f5807510f08c685af9a47
https://doi.org/10.1016/j.febslet.2013.12.025

Zobrazit plný text záznamu

The novel ATP-competitive inhibitor of the MET hepatocyte growth factor receptor EMD1214063 displays inhibitory activity against selected MET-mutated variants

Autor: Andree Blaukat, Michaela Medová, Daniel M. Aebersold, Benoît Pochon, Paola Francica, Wieslawa Blank-Liss, Bruno Streit, Adrian Keogh, Friedhelm Bladt, Deborah Stroka, Yitzhak Zimmer

Publikováno v: Scopus-Elsevier
Molecular Cancer Therapeutics

The receptor tyrosine kinase MET is a prime target in clinical oncology due to its aberrant activation and involvement in the pathogenesis of a broad spectrum of malignancies. Similar to other targeted kinases, primary and secondary mutations seem to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec7a8d841d1af0551219310a7cc4ea78
https://pubmed.ncbi.nlm.nih.gov/24061647

Zobrazit plný text záznamu

Abstract 1786: Characterization of the inhibitory capacity of EMD1214063, a novel small molecule inhibitor of the MET hepatocyte growth factor receptor on a panel of MET mutated variants

Autor: Friedhelm Bladt, Michaela Medová, Yitzhak Zimmer, Benoît Pochon, Deborah Stroka, Daniel M. Aebersold, Andree Blaukat

Publikováno v: Cancer Research. 72:1786-1786

The receptor tyrosine kinase MET is a prime target in clinical oncology because of its aberrant activation in a broad spectrum of malignancies. Here, we tested the anti tumor activity of a novel MET inhibitor, EMD1214063, on cancer cells overexpressi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d94e9767b3213e842643c24b72fcfe6d
https://doi.org/10.1158/1538-7445.am2012-1786

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání